BBAI vs PTRN

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score and negative profitability metrics raise concerns. Despite strong liquidity (Current Ratio: 3.13), the company is deeply unprofitable with a -295.61% profit margin and -120.34% ROE, while revenue is declining YoY by -20.10%. Valuation multiples are extremely stretched with a Price/Sales of 18.48 and a negative Forward P/E of -29.10, suggesting speculative pricing unsupported by fundamentals. Insider selling and weak earnings surprise history further undermine confidence.

PTRN presents a stark contrast between strong growth metrics and poor operational health, as evidenced by a weak Piotroski F-Score of 2/9. While the company exhibits impressive YoY revenue growth of 40.30% and a reasonable Forward P/E of 23.01, its net profit margins are razor-thin at 0.65%. The balance sheet is clean with very low debt (D/E 0.05) and strong liquidity (Current Ratio 2.34), but the lack of operational efficiency drags down the deterministic health scores. The stock is currently viewed as a speculative growth play with a significant gap between its current price and analyst targets.